You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 293 No. 10, March 9, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Statistics and Research Methods
 •Hypertension
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Antihypertensive Agents and Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Aboyans and colleagues raise a number of salient issues regarding the CAMELOT study. With regard to selection bias, we did examine the demographic characteristics of patients in the IVUS substudy; their clinical characteristics were very similar to those enrolled in the main trial. With regard to comparisons with the REVERSAL trial,2 we were reluctant to make any statements regarding the relative effects of statins and antihypertensive agents on atherosclerosis progression, primarily because comparing 2 different trial populations is hazardous even when demographic characteristics are similar. In addition, treatment duration was 18 months in REVERSAL and 24 months in CAMELOT.

We concur with the observation that amlodipine demonstrated the greatest effect on the "hospitalization for angina" end point. We provided post hoc data analysis on rates of death, myocardial infarction, and stroke to emphasize that results for these "hard" end points were similar in both active treatment groups. . . . [Full Text of this Article]

Steven E. Nissen, MD
nissens@ccf.org
Department of Cardiovascular Medicine
Cleveland Clinic Foundation
Cleveland, Ohio

For the CAMELOT Investigators



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure: The CAMELOT Study: A Randomized Controlled Trial
, , , , , , , , , , and
JAMA. ;292():2217-2225.
FULL TEXT  

Antihypertensive Agents and Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure
, , and
JAMA. ;293():1187-1187.
FULL TEXT  

Antihypertensive Agents and Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure
, , and
JAMA. ;293():1187-1188.
FULL TEXT  

Antihypertensive Agents and Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure
and
JAMA. ;293():1188-1188.
FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.